Globalagliatin Hydrochloride vs PB-201
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline
Globalagliatin Hydrochloride
Developed by Eli Lilly and partners
NCT03414892 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
the mean change in glucose area under curve (AUC) from baseline. (28 days): Phase Ib, 28-day multiple ascending dose study of globalagliatin (glucokinase activator) in 24 Chinese T2DM patients (3:1 randomization, NCT03414892): high-dose globalagliatin significantly reduced FPG by LS mean -4.08 mmol/L (95% CI -5.05 to -3.12, P<0.01) vs placebo, plus significant reductions in 24-h glucose AUC and glycated albumin; mildly elevated incidences of hypoglycemia and hypertriglyceridemia; well tolerated with favorable PK. (met)
Result source: NCT03414892
PB-201
Developed by PegBio and partners
NCT05102149 · Phase 3 · status unknown
This is a randomized, fully blinded trial with both an active and a placebo comparator, testing a recognized clinical measure (HbA1c) in a reasonably large group of patients, but no results are available yet to confirm whether PB-201 met its goal.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Globalagliatin Hydrochloride | PB-201 |
|---|---|---|
| HbA1c, change | —Not reported | —Not reported |
| Body weight, change (kg) | —Not reported | —Not reported |
| HbA1c below 7% | —Not reported | —Not reported |
| Fasting plasma glucose, change | —Not reported | —Not reported |
| 3-point MACE (% with event) | —Not reported | —Not reported |
HbA1c, change
- Globalagliatin Hydrochloride
- —Not reported
- PB-201
- —Not reported
Body weight, change (kg)
- Globalagliatin Hydrochloride
- —Not reported
- PB-201
- —Not reported
HbA1c below 7%
- Globalagliatin Hydrochloride
- —Not reported
- PB-201
- —Not reported
Fasting plasma glucose, change
- Globalagliatin Hydrochloride
- —Not reported
- PB-201
- —Not reported
3-point MACE (% with event)
- Globalagliatin Hydrochloride
- —Not reported
- PB-201
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
PB-201: no structured comparison results are available for Type 2 Diabetes.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Globalagliatin Hydrochloride's landscape · PB-201's landscape